Jingoro Shimada

1.5k total citations
71 papers, 1.2k citations indexed

About

Jingoro Shimada is a scholar working on Pharmacology, Epidemiology and Molecular Biology. According to data from OpenAlex, Jingoro Shimada has authored 71 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pharmacology, 21 papers in Epidemiology and 19 papers in Molecular Biology. Recurrent topics in Jingoro Shimada's work include Antibiotics Pharmacokinetics and Efficacy (25 papers), Pneumonia and Respiratory Infections (13 papers) and Antibiotic Resistance in Bacteria (12 papers). Jingoro Shimada is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (25 papers), Pneumonia and Respiratory Infections (13 papers) and Antibiotic Resistance in Bacteria (12 papers). Jingoro Shimada collaborates with scholars based in Japan, United States and France. Jingoro Shimada's co-authors include Shigeru Kohno, Hiroshi Kida, Masashi Mizuguchi, Yutaka Saisho, Akiko Shiraishi, Yoshihiro Inoué, Toshiko Hada, Hajime Hamashima, Takayuki Katsube and Nobuo Hirotsu and has published in prestigious journals such as Nucleic Acids Research, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Jingoro Shimada

69 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jingoro Shimada Japan 17 533 357 257 257 196 71 1.2k
Susan L. Pendland United States 20 224 0.4× 298 0.8× 259 1.0× 283 1.1× 129 0.7× 46 1.4k
J M Hamilton-Miller United Kingdom 17 222 0.4× 257 0.7× 298 1.2× 197 0.8× 189 1.0× 39 1.2k
Jane E. Ambler United States 12 440 0.8× 495 1.4× 308 1.2× 533 2.1× 283 1.4× 24 1.2k
Tsu-Lan Wu Taiwan 18 278 0.5× 133 0.4× 244 0.9× 406 1.6× 281 1.4× 24 1.2k
Alisa W. Serio United States 17 235 0.4× 369 1.0× 472 1.8× 582 2.3× 175 0.9× 38 1.4k
Paul Majcherczyk Switzerland 24 506 0.9× 248 0.7× 616 2.4× 213 0.8× 652 3.3× 37 1.6k
Darren Abbanat United States 19 294 0.6× 565 1.6× 495 1.9× 821 3.2× 272 1.4× 42 1.7k
J Pierre France 15 368 0.7× 131 0.4× 495 1.9× 256 1.0× 180 0.9× 34 1.6k
Fumiaki Ikeda Japan 26 881 1.7× 525 1.5× 404 1.6× 286 1.1× 1.1k 5.6× 77 2.3k
Shōgo Kuwahara Japan 22 447 0.8× 643 1.8× 429 1.7× 346 1.3× 631 3.2× 82 1.7k

Countries citing papers authored by Jingoro Shimada

Since Specialization
Citations

This map shows the geographic impact of Jingoro Shimada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingoro Shimada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingoro Shimada more than expected).

Fields of papers citing papers by Jingoro Shimada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingoro Shimada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingoro Shimada. The network helps show where Jingoro Shimada may publish in the future.

Co-authorship network of co-authors of Jingoro Shimada

This figure shows the co-authorship network connecting the top 25 collaborators of Jingoro Shimada. A scholar is included among the top collaborators of Jingoro Shimada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingoro Shimada. Jingoro Shimada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saisho, Yutaka, et al.. (2018). Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 62(3). 92 indexed citations
2.
Yamaguchi, Hiroki, et al.. (2007). Post-Marketing Surveillance of the Safety of Levofloxacin in Japan. Chemotherapy. 53(2). 85–103. 13 indexed citations
3.
Kamidono, Sadao, Soichi Arakawa, Takaoki Hirose, et al.. (2005). Double-blind, controlled study to evaluate safety and efficacy of doripenem and meropenem in patients with complicated urinary tract infection. 53. 244–259. 3 indexed citations
4.
Saitô, Atsushi, Akira Watanabe, Nobuki Aoki, et al.. (2005). A dose-finding study on doripenem in chronic respiratory tract infection. 53. 169–184. 1 indexed citations
5.
Saitô, Atsushi, Akira Watanabe, Koichiro Nakata, et al.. (2005). Comparative study of doripenem and meropenem in respiratory infections. Phase III double-blind comparative study. 53. 185–204. 3 indexed citations
6.
Saito, Atsushi, et al.. (2005). A study of doripenem efficacy and safety in internal medicine. Chemotherapy. 53(1). 157–168. 1 indexed citations
7.
Inoué, Yoshihiro, Akiko Shiraishi, Toshiko Hada, Hajime Hamashima, & Jingoro Shimada. (2004). The Antibacterial Effects of Myrcene on Staphylococcus aureus and Its Role in the Essential Oil of the Tea Tree (Melaleuca alternifolia). Natural medicines = 生薬學雜誌. 58(1). 10–14. 21 indexed citations
8.
Hada, Toshiko, Akiko Shiraishi, Yoshihiro Inoué, et al.. (2003). Inhibitory effects of terpenes on the growth of Staphylococcus aureus. Natural medicines = 生薬學雜誌. 57(2). 64–67. 24 indexed citations
9.
Shôji, Yôko, et al.. (1998). Enhancement of Anti-Herpetic Activity of Antisense Phosphorothioate Oligonucleotides 5′ End Modified with Geraniol. Journal of drug targeting. 5(4). 261–273. 9 indexed citations
10.
Yanagawa, Akira, et al.. (1995). Anti-bacterial and anti-fungal effect of several anti-rheumatic drugs.. Ensho. 15(3). 261–264. 2 indexed citations
11.
Nakagawa, Takemasa, Jingoro Shimada, Yutaka Mizushima, Toshiaki Takaishi, & Yutaka Morita. (1995). Effect of ciprofloxacin on histamine release from human and rat mast cells.. Ensho. 15(4). 337–338. 3 indexed citations
12.
Nomura, Masakatsu, et al.. (1995). Functional comparison of newly developed DPI device with already marketed Spinhaler. Ensho. 16(2). 103–110. 1 indexed citations
13.
Shôji, Yôko, Jingoro Shimada, & Yutaka Mizushima. (1995). The factors to reflect on the subcellular distribution of antisense DNA.. Drug Delivery System. 10(2). 85–90. 2 indexed citations
14.
Shôji, Yôko, et al.. (1994). Characteristic of cellular uptake mechanism and subcellular distribution of phosphorothioate oligodeoxynucleotides in CHRC5 cells.. Drug Delivery System. 9(1). 19–24. 1 indexed citations
15.
Higaki, Megumu, et al.. (1993). Effects of IL-1.BETA. expression in synobiocytes from patients with RA by antisense DNA.. Drug Delivery System. 8(4). 257–261. 1 indexed citations
16.
Yoshida, Masaki, Jingoro Shimada, Atsushi Saitô, et al.. (1993). Clinical studies of loracarbef. Chemotherapy. 41. 184–187. 3 indexed citations
17.
Saito, Atsushi, Jingoro Shimada, Seiji Hori, et al.. (1990). Effect of antacid on gastrointestinal absorption of fleroxacin in healthy humans. Chemotherapy. 38. 344–346. 2 indexed citations
18.
Hori, Seiji, et al.. (1988). Effect of T-3262 and its structural derivatives on GABA receptor binding. Chemotherapy. 36(9). 116–120. 5 indexed citations
19.
Saitô, Atsushi, et al.. (1984). Clinical studies on ceftriaxone (Ro 13-9904). Chemotherapy. 32. 259–278. 2 indexed citations
20.
Matsumoto, Fumio, et al.. (1980). CLINICAL STUDIES OF CEFOTAXIME. 28(1). 218–227. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026